NorthStar Secures Up to $185 Million Growth Financing Led by Hercules Capital to Scale Actinium-225

[Marlin]

NorthStar Secures Up to $185 Million Growth Financing Led by Hercules Capital to Scale Actinium-225 Production and Radiopharmaceutical Manufacturing for Next-Generation Precision Cancer Therapies

https://www.businesswire.com/news/home/20260929548670/en/NorthStar-Secures-Up-to-%24185-Million-Growth-Financing-Led-by-Hercules-Capital-to-Scale-Actinium-225-Production-and-Radiopharmaceutical-Manufacturing-for-Next-Generation-Precision-Cancer-Therapies

[Core Content]

NorthStar Medical Technologies secured a growth capital facility of up to $185 million led by Hercules Capital to expand its radiopharmaceutical campus in Beloit, Wisconsin. The funding will scale commercial production of no-carrier-added Actinium-225 using electron-accelerator technology, supporting a growing supply chain for targeted cancer therapies and clinical trials.

BELOIT, Wis., September 29, 2026--NorthStar Medical Technologies, LLC (NorthStar), the first commercial-scale producer of no-carrier-added actinium-225 (n.c.a. Ac-225) using electron-accelerator technology, today announced a multi-year growth capital facility of up to $185 million with Hercules Capital, Inc. (NYSE: HTGC) to support NorthStar's...

The agreement supports NorthStar's continued commercial scale-up investment leveraging its industry-leading scientific talent and vertically integrated radiopharmaceutical campus, where it provides clinical and commercial isotope production and radiopharmaceutical manufacturing, including comprehensive cGMP services through its state-of-the-art CDMO.

Related coverage at Yahoo Finance:
https://finance.yahoo.com/healthcare/articles/northstar-secures-185-million-growth-110000230.html